Sunitinib
Sunitinib is an active ingredient of the class «ALK inhibitor».
Chemical compound
Boxed warning (US label)
Hepatotoxicity. Hepatotoxicity may be severe, and in some cases, fatal. Monitor hepatic function and interrupt, dose reduce, or discontinue SUTENT as recommended.
What it is used for
- Renal cell carcinoma
- Gastrointestinal stromal tumor
- Carcinoid tumor
- Rare urinary tract tumor
- Gastrointestinal carcinoma
- Connective tissue neoplasm
- Kidney cancer
- Neuroendocrine carcinoma
- Pancreatic cancer
- Thymus cancer
- Renal pelvis carcinoma
- Renal clear cell carcinoma
- Neoplasm
- Neuroendocrine tumor
SUTENT is a kinase inhibitor indicated for: • treatment of adult patients with gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate. • treatment of adult patients with advanced renal cell carcinoma (RCC). • adjuvant treatment of adult patients at…
Gastrointestinal stromal tumour (GIST) Sutent is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (GIST) in adults after failure of imatinib mesilate treatment due to resistance or intolerance.
How it works
- Macrophage colony stimulating factor receptor inhibitor
- Stem cell growth factor receptor inhibitor
- Tyrosine-protein kinase receptor FLT3 inhibitor
- Platelet-derived growth factor receptor inhibitor
- Vascular endothelial growth factor receptor inhibitor
- Tyrosine-protein kinase receptor RET inhibitor
Class: ALK inhibitor
Common side effects
The following clinically significant adverse reactions are described elsewhere in the labeling. • Hepatotoxicity • Cardiovascular Events • QT Interval Prolongation and Torsade de Pointes • Hypertension • Hemorrhagic Events • Tumor Lysis Syndrome • Thrombotic Microangiopathy • Proteinuria • Dermatologic Toxicities •…
Pregnancy and breastfeeding
Based on animal reproduction studies and its mechanism of action, SUTENT can cause fetal harm when administered to a pregnant woman. There are no available data in pregnant women to inform a drug-associated risk.
Interactions
- Clarithromycin — long QT syndrome
- Crizotinib — long QT syndrome, bone marrow failure
- Erythromycin — long QT syndrome
- Posaconazole — long QT syndrome
- Voriconazole — long QT syndrome
Brand names
United States
Sutent
European Union
Sunitinib Accord · Sutent
Canada
Auro-Sunitinib · Eugia-Sunitinib · Nat-Sunitinib · Sandoz Sunitinib · Sutent · Taro-Sunitinib · Teva-Sunitinib
Approval status
- US Food and Drug Administration
- prescription · since 2006
- European Medicines Agency
- authorised · since 2006
- Health Canada
- prescription · marketed
- First approval anywhere
- 2006
Codes
- ATC
- L01EX01, L01XE04
- RxNorm CUI
- 357977
- ChEMBL
- CHEMBL535
- PubChem CID
- 5329102
- UNII
- V99T50803M
- Wikidata
- Q417542
Frequently asked questions
What is Sunitinib used for?
Sunitinib is used for: Renal cell carcinoma, Gastrointestinal stromal tumor, Carcinoid tumor, Rare urinary tract tumor, Gastrointestinal carcinoma, Connective tissue neoplasm, Kidney cancer, and Neuroendocrine carcinoma.
What kind of medicine is Sunitinib?
Sunitinib is an active ingredient of the class «ALK inhibitor».
What are the brand names of Sunitinib?
Brand names of Sunitinib include Sutent, Sunitinib Accord, Auro-Sunitinib, Eugia-Sunitinib, Nat-Sunitinib, Sandoz Sunitinib, Taro-Sunitinib, and Teva-Sunitinib.
Medicines in the same class
Sources and licences
- ChEMBL (CC BY-SA 3.0)
- Wikidata (CC0 1.0)
- openFDA / DailyMed (public domain)
- European Medicines Agency (reuse with acknowledgement)
- Health Canada Drug Product Database (Open Government Licence – Canada)